DEA extends telemedicine flexibilities through 2025
Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications” (RIN 1117-ZA06) will ... including as Adderall, Buprenorphine, and Ketamine, without in-person evaluations through December 31, 2025